I don't see how this is poor? Does it not state an increase in revenue? I feel that the market is missing the big picture with BXN. Good management. Unique and innovative products with scientific and clinical evidence of their validity. Excellent distribution and market potential - ASIA. I guess the recent decline in SP is due to the typical "sell on good news" .... or have I missed something? This has happened previously with BXN, earlier this year. People sold on good news. The SP went down to ~ 0.7 before racing back upto ~ 0.115. Now it appears to be down again. I have faith in this company. The potential success seems to be highly probably given it's background. This imo.
Add to My Watchlist
What is My Watchlist?
